A Phase 2 interventional study of Memantine in Compulsive Buying, sponsored by University of Minnesota. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-29.
Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment
This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.
The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
10-30mg, memantine
Drug: Memantine
10-30mg, by mouth, daily
Also known as: Namenda
Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)
The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms
Time frame: from study start to study end (8-weeks) and is Investigator rated
December 2008 - August 2010
| Milestone | Memantine |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms
| units on a scale | Memantine |
|---|---|
| Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) | 22 ± 4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine | — | 0/10 (0%) | 0/10 (0%) |
| Age, Categorical(Participants) | Memantine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 0 |
| Age, Continuous(years) | Memantine |
|---|---|
| Mean | 32 ± 12.4 |
| Sex: Female, Male(Participants) | Memantine |
|---|---|
| Female | 9 |
| Male | 1 |
| Region of Enrollment(participants) | Memantine |
|---|---|
| United States | 10 |
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Minnesota